An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma

Despite exciting achievements with some malignancies, immunotherapy for hypoimmunogenic cancers, especially glioblastoma (GBM), remains a formidable clinical challenge. Poor immunogenicity and deficient immune infiltrates are two major limitations to an effective cancer-specific immune response. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Qiujun, Chen, Sunhui, He, Huining, Chen, Jixiang, Ding, Xinyi, Wang, Dongdong, Yang, Jiangang, Guo, Pengcheng, Li, Yang, Kim, Jisu, Sheng, Jianyong, Gao, Chao, Yin, Bo, Zheng, Shihao, Wang, Jianxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692361/
https://www.ncbi.nlm.nih.gov/pubmed/38045037
http://dx.doi.org/10.1016/j.apsb.2023.06.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692361/
https://www.ncbi.nlm.nih.gov/pubmed/38045037
http://dx.doi.org/10.1016/j.apsb.2023.06.010

Ejemplares similares